---
category: listing
circular_id: 4e74d9dc94a35502
date: '2025-08-26'
description: 13,98,463 new equity shares of Kilitch Drugs (I) Ltd listed and permitted
  to trade from August 28, 2025
draft: false
guid: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={024B36BF-4855-4BFE-808A-EEA9055EC1B1}&noticeno=20250826-58&dt=08/26/2025&icount=58&totcount=60&flag=0
impact: low
impact_ranking: low
importance_ranking: low
justification: Routine rights issue listing with limited market impact
pdf_url: https://www.bseindia.com/markets/MarketInfo/DownloadAttach.aspx?id=20250826-58&attachedId=
processing:
  attempts: 1
  content_hash: 11f713f535b30098
  processed_at: '2025-08-26T18:29:21.298682'
  processor_version: '2.0'
  stage: completed
  status: published
published_date: '2025-08-26T16:30:58+00:00'
rss_url: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={024B36BF-4855-4BFE-808A-EEA9055EC1B1}&noticeno=20250826-58&dt=08/26/2025&icount=58&totcount=60&flag=0
severity: low
source: bse
stocks:
- KILITCH
tags:
- equity-shares
- rights-issue
- new-listing
- kilitch-drugs
title: Listing of New Securities of Kilitch Drugs (I) Ltd
---

## Summary

Kilitch Drugs (I) Ltd has listed 13,98,463 new equity shares issued through a rights offering. The shares are available for trading on BSE starting August 28, 2025, and rank pari-passu with existing equity shares.

## Key Points

- 13,98,463 new equity shares of Rs. 10/- each
- Issued at premium of Rs. 347/- per share on rights basis
- ISIN: INE729D01010
- Scrip Code: 524500
- Distribution Numbers: 16082320 to 17480782

## Regulatory Changes

No regulatory changes introduced.

## Compliance Requirements

Trading members are informed of the new securities available for trading.

## Important Dates

- **Allotment Date**: August 25, 2025
- **Trading Commencement**: August 28, 2025
- **Notice Date**: August 26, 2025

## Impact Assessment

Routine rights issue listing with minimal market impact. The new shares increase the company's equity base and provide additional liquidity for existing shareholders who participated in the rights offering.